Core Viewpoint - The company has entered into an exclusive collaboration with Zhejiang Zhongshen Innovation Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, aiming to accelerate the transition from laboratory results to clinical applications [1] Group 1: Collaboration Details - The company and Zhongshen Innovation have signed a Technical Development Cooperation Agreement and a supplementary agreement for the BIOS-0629 project [1] - The project is currently in the PCC stage and targets solid tumors as its indication [1] - The company will handle research, clinical trials, and registration applications, while Zhongshen Innovation will manage R&D transformation, post-market production, sales, and market expansion in the Greater China region [1] Group 2: Financial Aspects - Following the signing of the contract, Zhongshen Innovation will pay a milestone fee of 300 million yuan based on R&D milestones [1] - Upon the product's launch in the Greater China region, the company will receive a 10% commission on sales revenue [1] Group 3: Strategic Goals - The collaboration aims to leverage both parties' resources and technological advantages in innovative drug development to enhance collaborative innovation [1] - The partnership is expected to expedite the transition of the BIOS-0629 project from laboratory achievements to clinical applications, promoting innovative outcomes [1]
百诚医药与众神创新就创新药BIOS-0629项目达成授权合作